Patents by Inventor Philip Stephens

Philip Stephens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230009430
    Abstract: In some embodiments, features related to inter-beat intervals (IBI) detected by a PPG sensor of a wearable device are extracted and provided to a cardiovascular classifier in order to detect likely instances of a cardiac condition such as atrial fibrillation. Some embodiments use features related to the entropy of the IBI data to improve the predictions generated by the cardiovascular classifier. In some embodiments, co-information between the IBI data and IBI data gathered from healthy and AF populations is determined in order to derive features that represent the probability that a given sample of IBI data represents AF or a normal sinus rhythm. In response to determining likely instances of AF based on these features, the wearable device may obtain clinically acceptable data, such as an ECG, to be transmitted to a separate device for review by a clinician.
    Type: Application
    Filed: July 22, 2022
    Publication date: January 12, 2023
    Inventor: Philip Stephens
  • Patent number: 11399775
    Abstract: In some embodiments, features related to inter-beat intervals (IBI) detected by a PPG sensor of a wearable device are extracted and provided to a cardiovascular classifier in order to detect likely instances of a cardiac condition such as atrial fibrillation. Some embodiments use features related to the entropy of the IBI data to improve the predictions generated by the cardiovascular classifier. In some embodiments, co-information between the IBI data and IBI data gathered from healthy and AF populations is determined in order to derive features that represent the probability that a given sample of IBI data represents AF or a normal sinus rhythm. In response to determining likely instances of AF based on these features, the wearable device may obtain clinically acceptable data, such as an ECG, to be transmitted to a separate device for review by a clinician.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: August 2, 2022
    Assignee: Verily Life Sciences LLC
    Inventor: Philip Stephens
  • Publication number: 20210052175
    Abstract: In some embodiments, features are extracted from a waveform generated by a photoplethysmograph (PPG) sensor of a wearable device. These features are used to train and use classifier models to detect likely instances of cardiovascular conditions that affect blood flow during a cardiac cycle, including but not limited to atrial fibrillation. In some embodiments, the features are extracted based on the shape of the waveform, including one or more of an amplitude, an upslope rate, a downslope rate, and differentials thereof over time. In some embodiments, data from an inertial measurement unit (IMU) is used to filter and/or compensate for motion artifacts in the PPG data. The use of data generated by PPG sensors allows long-term, non-invasive monitoring for cardiovascular conditions without requiring further actions to be taken by the user to obtain data using other means.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 25, 2021
    Inventors: Philip Stephens, Michael McConnell, Allen Keel
  • Publication number: 20210052229
    Abstract: In some embodiments, features related to inter-beat intervals (IBI) detected by a PPG sensor of a wearable device are extracted and provided to a cardiovascular classifier in order to detect likely instances of a cardiac condition such as atrial fibrillation. Some embodiments use features related to the entropy of the IBI data to improve the predictions generated by the cardiovascular classifier. In some embodiments, co-information between the IBI data and IBI data gathered from healthy and AF populations is determined in order to derive features that represent the probability that a given sample of IBI data represents AF or a normal sinus rhythm. In response to determining likely instances of AF based on these features, the wearable device may obtain clinically acceptable data, such as an ECG, to be transmitted to a separate device for review by a clinician.
    Type: Application
    Filed: August 19, 2019
    Publication date: February 25, 2021
    Inventor: Philip Stephens
  • Patent number: 10182746
    Abstract: Systems and techniques are disclosed for decoupling a wearable sensor's location on a user from the body movements desired to be measured by the sensor. Sensor data can be dynamically analyzed to determine a reference event (e.g., a static pose), which can be used to generate or update a transformation parameter (e.g., a quaternion or a rotational matrix). The transformation parameter can be applied to sensor data to transform the sensor data from the sensor's frame of reference to a global frame of reference. Once transformed, the movement data in the global frame can be analyzed to identify sensor-location-agnostic biomechanical features (e.g., body movements or movement trends), which can be further analyzed to identify probable or potential diagnoses correlated with the identified biomechanical features.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: January 22, 2019
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Emre Demiralp, Hongsheng Wang, Philip Stephens
  • Publication number: 20150164947
    Abstract: The invention relates to the isolation and use of a novel progenitor cell population from the lamina propria of the oral mucosa. The novel progenitor cell population is highly proliferative and can be differentiated into a range of cell lineages. Further, these novel progenitor cells possess immunomodulatory activity and so can be used in the allogeneic transfer of tissue or to help combat immune disorders.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 18, 2015
    Applicant: University College Cardiff Consultants Limited
    Inventors: Philip Stephens, Lindsay Catrina Davies
  • Patent number: 8491852
    Abstract: An indicator device adapted give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetermined minimum level which is characteristic of an infected wound. Also provided system for use in the diagnosis and treatment of wounds comprising the inventive diagnostic device and a wound dressing comprising at least one antimicrobial agent for selective application to infected wounds. Also provided are methods of diagnosis and treatment by means of the inventive device and system.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: July 23, 2013
    Assignee: Systagenix Wound Management (US), Inc.
    Inventors: Breda Mary Cullen, Rachael Clark, Philip Stephens, Ryan Moseley
  • Publication number: 20120010099
    Abstract: The present invention relates to a method of determining the microbial bioburden in a wound (in particular a diabetic ulcer) in a test subject, the method comprising the step of measuring the level of a cytokine in a wound sample, wherein a cytokine level lower than a reference level indicates a significant microbial bioburden in the wound (or a cytokine level higher than a reference level indicates an insignificant microbial bioburden in the wound). The invention provides methods of diagnosis, prognosis and treatment of wound infection, and devices and kits for use in such methods.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 12, 2012
    Applicant: Systagenix Wound Management (US), INC.
    Inventors: Philip Stephens, Ryan Moseley, Rachael Clark, Breda Mary Cullen
  • Patent number: 8012698
    Abstract: The present invention relates to a method of determining the microbial bioburden in a wound (in particular a diabetic ulcer) in a test subject, the method comprising the step of measuring the level of a cytokine in a wound sample, wherein a cytokine level lower than a reference level indicates a significant microbial bioburden in the wound (or a cytokine level higher than a reference level indicates an insignificant microbial bioburden in the wound). The invention provides methods of diagnosis, prognosis and treatment of wound infection, and devices and kits for use in such methods.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: September 6, 2011
    Assignee: Systagenix Wound Management (US), Inc.
    Inventors: Philip Stephens, Ryan Moseley, Rachael Clark, Breda Mary Cullen
  • Publication number: 20110110900
    Abstract: The invention relates to the isolation and use of a novel progenitor cell population from the lamina propria of the oral mucosa. The novel progenitor cell population is highly proliferative and can be differentiated into a range of cell lineages. Further, these novel progenitor cells possess immunomodulatory activity and so can be used in the allogeneic transfer of tissue or to help combat immune disorders.
    Type: Application
    Filed: June 11, 2009
    Publication date: May 12, 2011
    Inventors: Philip Stephens, Lindsay Catrina Davies
  • Publication number: 20100166694
    Abstract: The present invention relates to a method of determining the microbial bioburden in a wound (in particular a diabetic ulcer) in a test subject, the method comprising the step of measuring the level of a cytokine in a wound sample, wherein a cytokine level lower than a reference level indicates a significant microbial bioburden in the wound (or a cytokine level higher than a reference level indicates an insignificant microbial bioburden in the wound). The invention provides methods of diagnosis, prognosis and treatment of wound infection, and devices and kits for use in such methods.
    Type: Application
    Filed: March 31, 2008
    Publication date: July 1, 2010
    Applicant: Ethicon ,Inc.
    Inventors: Philip Stephens, Ryan Moseley, Rachael Clark, Breda Mary Cullen
  • Publication number: 20090299161
    Abstract: An indicator device adapted give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetermined minimum level which is characteristic of an infected wound. Also provided system for use in the diagnosis and treatment of wounds comprising the inventive diagnostic device and a wound dressing comprising at least one antimicrobial agent for selective application to infected wounds. Also provided are methods of diagnosis and treatment by means of the inventive device and system.
    Type: Application
    Filed: April 24, 2006
    Publication date: December 3, 2009
    Inventors: Breda Mary Cullen, Rachael Clark, Philip Stephens, Ryan Moseley
  • Patent number: 6362817
    Abstract: A computer-based system for designing and using three-dimensional environments over a bandwidth limited network such as the Internet. The system allows an environment to be specified as a series of two-dimensional grids of text characters. Each character occupies a single grid position and represents an object in the environment. Objects can be given characteristics such as texture maps, and associated images and sounds that are triggered by events such as a user approaching the object. An object or image can be a hyperlink so that, when clicked or moved upon, the user is transported to a new location. A basic set of objects and media (images and sounds) is provided so that a designer of an environment does not have to perform low-level three-dimensional modeling. Objects can behave differently when placed near one another. For example, walls fuse together to provide a longer wall.
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: March 26, 2002
    Assignee: IN3D Corporation
    Inventors: Michael Powers, Philip Stephens